Sigurdardottir, H. L.
Kranz, G. S. http://orcid.org/0000-0002-3892-1804
Rami-Mark, C.
James, G. M.
Vanicek, T.
Gryglewski, G.
Berroterán-Infante, N. http://orcid.org/0000-0002-9247-6457
Kautzky, A.
Hienert, M.
Traub-Weidinger, T.
Mitterhauser, M.
Wadsak, W. http://orcid.org/0000-0003-4479-8053
Hartmann, A. M.
Hacker, M.
Rujescu, D.
Kasper, S.
Lanzenberger, R. http://orcid.org/0000-0003-4641-9539
Article History
Received: 23 March 2018
Revised: 4 April 2019
Accepted: 11 April 2019
First Online: 5 August 2019
Compliance with ethical standards
:
: The authors declare that they have no conflict of interest in relevance to this work. S. Kasper received grants/research support, consulting fees, and/or honoraria within the last 3 years from Angelini, AOP Orphan Pharmaceuticals AG, Celegne GmbH, Eli Lilly, Janssen-Cilag Pharma GmbH, KRKA-Pharma, Lundbeck A/S, Mundipharma, Neuraxpharm, Pfizer, Sanofi, Sage, Schwabe, Servier, Shire, Sumitomo Dainippon Pharma Co. Ltd., Sun Pharmaceuticals Industries Ltd. and Takeda. R. Lanzenberger received conference speaker honorarium within the last three years from Shire and support from Siemens Healthcare regarding clinical research using PET/MR. He is shareholder of BM Health GmbH since 2019.